FrancophonIA/ELRC3.0 huggingface dataset:
English: For products containing valsartan, the existing product information shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the agreed wording as provided below
Romanian: Pentru medicamentele care conţin valsartan, se vor modifica informaţiile existente privind produsul (se va introduce, înlocui sau elimina text, după cum este necesar) pentru a reflecta textul aprobat de mai jos
English: For all ACE-inhibitors with wording in section 4.2 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Romanian: Cu privire la toţi inhibitorii ECA menţionaţi la pct. 4.2, despre care se specifică că pot fi utilizaţi în monoterapie sau concomitent cu alte medicamente antihipertensive, trebuie adăugată următoarea precizare: „(vezi pct. 4.3, 4.4, 4.5 şi 5.1)”.
English: For all ACE-inhibitors with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Romanian: Cu privire la toţi inhibitorii ECA menţionaţi la pct. 4.1, despre care se specifică că pot fi utilizaţi în monoterapie sau concomitent cu alte medicamente antihipertensive, trebuie adăugată următoarea precizare: „(vezi pct. 4.3, 4.4, 4.5 şi 5.1)”.
English: For angiotensin II receptor blockers with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Romanian: Cu privire la toţi blocanţii receptorilor angiotensinei II menţionaţi la pct. 4.1, despre care se specifică că pot fi utilizaţi în monoterapie sau concomitent cu alte medicamente antihipertensive, trebuie adăugată următoarea precizare: „(vezi pct. 4.3, 4.4, 4.5 şi 5.1)”.
English: For valsartan-containing products with wording in section 4.2 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Romanian: Cu privire la medicamentele care conţin valsartan menţionate la pct. 4.2, despre care se specifică că pot fi utilizaţi în monoterapie sau concomitent cu alte medicamente antihipertensive, trebuie adăugată următoarea precizare: „(vezi pct. 4.3, 4.4, 4.5 şi 5.1)”.
English: The following wording should be added to this section:
Romanian: La acest punct, trebuie adăugat următorul text:
English: For candesartan-containing products with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Romanian: Cu privire la medicamentele care conţin candesartan menţionate la pct. 4.1, despre care se specifică că pot fi utilizaţi în monoterapie sau concomitent cu alte medicamente antihipertensive, trebuie adăugată următoarea precizare: „(vezi pct. 4.3, 4.4, 4.5 şi 5.1)”.
English: For valsartan-containing products with wording in section 4.1 stating that they can be used alone or in combination with other antihypertensive agents, the following cross-reference should be added: “(see sections 4.3, 4.4, 4.5 and 5.1)”.
Romanian: Cu privire la medicamentele care conţin valsartan menţionate la pct. 4.1, despre care se specifică că pot fi utilizaţi în monoterapie sau concomitent cu alte medicamente antihipertensive, trebuie adăugată următoarea precizare: „(vezi pct. 4.3, 4.4, 4.5 şi 5.1)”.
English: If you are being treated with an ACE-inhibitor together with certain other medicines to treat your heart failure, which are known as mineralocorticoid receptors antagonists (MRA) (for example spironolactone, eplerenone) or betablockers (for example metoprolol).”
Romanian: Dacă sunteţi tratat cu un inhibitor al ECA împreună cu anumite alte medicamente pentru tratarea insuficienţei cardiace, cunoscute sub denumirea de antagonişti ai receptorilor de mineralocorticoizi
English: London, 19 March 2009 Doc.
Romanian: Londra, 19 martie 2009 Ref. doc.
English: Ref. EMEA/156698/2009
Romanian: EMEA/291355/2009
English: The application was at day 194 when the company withdrew.
Romanian: Cererea se afla în ziua 194 în momentul în care societatea a retras-o.
English: What is Cylatron?
Romanian: Ce este Cylatron?
English: This decreases the rate at which the substance is removed from the body and allows the medicine to be given less often.
Romanian: Astfel, se reduce rata la care substanţa este eliminată din organism şi permite administrarea mai puţin frecventă a medicamentului.
English: The main measure of effectiveness was the how long the patients survived until the disease came back.
Romanian: Principala măsură a eficacităţii a fost durata perioadei de supravieţuire a pacienţilor până la recidiva bolii.
English: Questions and answers on the withdrawal of the marketing application for Cylatron
Romanian: Întrebări şi răspunsuri privind retragerea cererii de introducere pe piaţă pentru Cylatron
English: Patients were either given Cylatron for up to five years or received no treatment.
Romanian: Pacienţilor fie li s-a administrat Cylatron timp de până la cinci ani, fie nu li s-a administrat niciun tratament.
English: The CHMP had concerns over side effects of Cylatron, particularly fatigue (tiredness) and depression.
Romanian: CHMP avea motive de îngrijorare cu privire la efectele secundare ale Cylatron, în special fatigabilitatea (oboseala) şi depresia.
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Romanian: Dacă sunteţi inclus într-un studiu clinic sau un într-un program de uz compasional şi aveţi nevoie de mai multe informaţii referitoare la tratamentul pe care îl urmaţi, adresaţi-vă medicului dumneavoastră curant.
English: The effects of Cylatron were first tested in experimental models before being studied in humans.
Romanian: Efectele Cylatron au fost testate pe modele experimentale, înainte de a fi studiate pe subiecţi umani.
English: Cylatron was studied in one main study involving 1,256 adults with stage III melanoma.
Romanian: Cylatron a fost studiat într-un studiu principal la care au participat 1 256 de adulţi cu melanom în stadiul III.
English: It was also concerned that, although the medicine showed some effects in delaying the return of the cancer, it had not been shown to be effective in increasing how long the patients survived.
Romanian: De asemenea, au existat îngrijorări cu privire la faptul că, deşi medicamentul a avut anumite efecte în întârzierea recidivei cancerului, nu s-a observat o eficacitate în privinţa creşterii perioadei de supravieţuire a pacienţilor.
English: What is happening with PegIntron and ViraferonPeg for the treatment of hepatitis C and with IntronA for the treatment of malignant melanoma?
Romanian: Ce se întâmplă cu PegIntron şi ViraferonPeg pentru tratamentul hepatitei C şi cu IntronA pentru tratamentul melanomului malign?
English: This withdrawal of application has no consequences on the use of PegIntron, ViraferonPeg and IntronA in their authorised indications, for which the balance of benefits and risks remains unchanged.
Romanian: Retragerea cererii nu are nicio consecinţă pentru utilizarea PegIntron, ViraferonPeg şi IntronA în indicaţiile autorizate, pentru care raportul beneficiu-risc rămâne neschimbat.
English: Based on the review of the initial documentation, the CHMP prepares a list of questions at day 120, which is sent to the company.
Romanian: Pe baza revizuirii documentaţiei iniţiale, CHMP întocmeşte o listă de întrebări în ziua 120, care este transmisă societăţii.
English: Melanoma is a type of skin cancer affecting cells called melanocytes.
Romanian: Melanomul este un tip de cancer de piele care afectează celulele numite melanocite.
English: Following the CHMP's opinion, it usually takes around two months for the European Commission to grant a licence.
Romanian: După adoptarea avizului CHMP, Comisia Europeană acordă, de regulă, autorizaţia în termen de circa două luni.
English: On 11 March 2009, SP Europe officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Cylatron for the adjuvant treatment of stage III melanoma.
Romanian: La 11 martie 2009, SP Europe a notificat oficial Comitetul pentru medicamente de uz uman (CHMP) despre intenţia de a-şi retrage cererea de introducere pe piaţă pentru Cylatron pentru tratamentul adjuvant al melanomului în stadiul III.
English: In melanoma, interferon alfa-2b is thought to work by suppressing the growth and multiplication of cancerous cells, by causing these cells to die and by stimulating the immune system (the body's natural defences) to attack and kill the cancer cells.
Romanian: În cazul melanomului, se consideră că interferonul alfa-2b acţionează oprind creşterea şi înmulţirea celulelor canceroase, provocând moartea acestor celule, şi prin stimularea sistemului imunitar (sistemul natural de apărare al organismului) pentru ca acesta să atace şi să omoare celulele canceroase.
English: Cylatron is a powder and solvent that is made up into a solution for injection.
Romanian: Cylatron este un medicament sub formă de pulbere şi solvent pentru soluţie injectabilă.
English: What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Cylatron?
Romanian: Care sunt consecinţele retragerii cererii pentru pacienţii implicaţi în studii clinice sau programe de uz compasional care utilizează Cylatron?
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials or compassionate programmes with Cylatron.
Romanian: Societatea a informat CHMP că nu există nicio consecinţă pentru pacienţii care sunt incluşi în prezent în studii clinice sau în programe de uz compasional cu Cylatron.
English: After the CHMP had assessed the responses from the company to a list of questions, there were still some unresolved issues outstanding.
Romanian: După ce CHMP evaluase răspunsurile societăţii şi întocmise o listă de întrebări, existau încă anumite aspecte nesoluţionate.
English: ‘Stage III' means that some cancer cells have spread to the lymph nodes (part of the lymphatic system that drains fluids from the body's tissues).
Romanian: „Stadiul III” înseamnă că unele celule canceroase s-au extins la ganglionii limfatici (parte a sistemului limfatic care drenează fluidele din ţesuturile organismului).
English: IntronA is authorised for the treatment of malignant melanoma after surgery, along with other diseases.
Romanian: IntronA este autorizat pentru tratamentul melanomului malign după intervenţia chirurgicală şi pentru alte boli.
English: Based on the review of the data and the company's response to the CHMP list of questions at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Cylatron could not have been approved for adjuvant treatment of stage III melanoma.
Romanian: Pe baza analizării informaţiilor şi a răspunsurilor societăţii la lista de întrebări a CHMP în momentul retragerii cererii, CHMP avea unele motive de îngrijorare şi a formulat un aviz provizoriu conform căruia Cylatron nu putea fi aprobat pentru tratamentul adjuvant în cazul melanomului în stadiul III.
English: When the study began, all of the patients had recently had surgery to remove lymph nodes containing melanoma cells.
Romanian: La începutul studiului, toţi pacienţii suferiseră recent o intervenţie chirurgicală pentru îndepărtarea ganglionilor limfatici care conţineau celule de melanom.
English: Cylatron was expected to be used in adults with stage III (advanced) melanoma as an add-on treatment after surgery, to prevent the disease from coming back.
Romanian: Cylatron ar fi trebuit să se utilizeze la adulţii cu melanom în stadiul III (avansat) ca tratament suplimentar după intervenţia chirurgicală, pentru prevenirea recidivei bolii.
English: It consists of a substance called interferon alfa-2b, which has been ‘pegylated' (coated with a chemical called polyethylene glycol).
Romanian: Aceasta constă dintr-o substanţă numită interferon alfa-2b, care a fost „pegilat” (acoperit cu un strat de substanţă chimică numită polietilen glicol).
English: What was Cylatron expected to be used for?
Romanian: Pentru ce ar fi trebuit să se utilizeze Cylatron?
English: How is Cylatron expected to work?
Romanian: Cum ar trebui să acţioneze Cylatron?
English: Cylatron was expected to be given to patients whose lymph nodes contained melanoma cells as visible under a microscope, but not when the cancer had caused the lymph nodes to become large enough to be felt through the skin.
Romanian: Cylatron trebuia să fie administrat pacienţilor ai căror ganglioni limfatici conţin celule de melanom vizibile la microscop, însă nu în stadiul în care cancerul a determinat creşterea ganglionilor limfatici în asemenea măsură încât pot fi simţiţi prin piele.
English: The CHMP normally takes up to 210 days to evaluate a new application.
Romanian: În mod normal, pentru evaluarea unei cereri noi, CHMP are nevoie de maxim 210 zile.
English: International non-proprietary name (INN): peginterferon alfa-2b
Romanian: Denumire comună internaţională (DCI): peginterferon alfa-2b
English: It contains the active substance peginterferon alfa-2b.
Romanian: Acesta conţine substanţa activă peginterferon alfa-2b.
English: Peginterferon alfa-2b has been authorised in the European Union (EU) since May 2000 as PegIntron and ViraferonPeg for the treatment hepatitis C. Unpegylated interferon alfa-2b has also been authorised in the EU since March 2000 as IntronA.
Romanian: Peginterferonul alfa-2b este autorizat în Uniunea Europeană (UE) din mai 2000 ca PegIntron şi ViraferonPeg pentru tratamentul hepatitei C.
English: The active substance in Cylatron, peginterferon alfa-2b, belongs to the group ‘interferons'.
Romanian: Substanţa activă din Cylatron, peginterferon alfa-2b, aparţine clasei de „interferoni”.
English: EU number
Romanian: Numărul UE
English: Invented name Strength Pharmaceutical
Romanian: Numele inventat
English: Package size
Romanian: Mărimea ambalajului
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, Marketing Authorisation Holders in the Member States
Romanian: Anexa I Lista cu denumirile comerciale, formele farmaceutice, concentrațiile, căile de administrare ale medicamentelor, deţinătorulii autorizației de punere pe piață în statele membre
English: Box 1711
Romanian: P.O. Box 1711
English: Intramuscular use intravenous use
Romanian: Administrare intramusculară administrare intravenoasă
English: Modified-release tablet
Romanian: Comprimat cu eliberare modificată
English: Modified-release capsule, hard
Romanian: Capsulă cu eliberare modificată
English: Lundbeck B.V.
Romanian: Lundbeck B.V. Gebouw Jupiter Herikerbergweg
English: Gebouw Jupiter Herikerbergweg 100 Postbus 12021
Romanian: Postbus 12021
English: --1 Inactivated influenza A virus/human, strain A/Jena/VI5258/2009(H1N1)pdm09 ≥ 16 HU* *HU = haemagglutinating units
Romanian: --1 Virus gripal A inactivat/uman Tulpină: A/Jena/VI5258/2009(H1N1)pdm09 ≥ 16 HU*
English: Target species
Romanian: Specii țintă
English: Strength Pharmaceutical form
Romanian: Concentrație Forma farmaceutică
English: Packaging Content
Romanian: Ambalare Conținut Dimensiunea ambalajului
English: Withdrawal period
Romanian: Timp de aşteptare
English: EU (MA) Number Invented name
Romanian: Număr UE
English: Annex A
Romanian: A. ETICHETARE
English: Johnson & Johnson, Lda.
Romanian: Portugalia Johnson & Johnson, Lda.
English: Al. Armii Ludowej 26 00-609 Warszawa Poland
Romanian: Al. Armii Ludowej 26 00-609 Warszawa Polonia
English: 2333 CR Leiden The Netherlands
Romanian: 2333 CR Leiden Olanda
English: Belgium Aktuapharma nv Ambachtenlaan 13E 3001 Leuven
Romanian: Aktuapharma nv Ambachtenlaan 13E 3001 Leuven Belgia
English: Carnaxide Portugal
Romanian: Carnaxide Portugalia
English: 26.200 28700 San Sebastián de los Reyes (Madrid) Spain
Romanian: 26.200 28700 San Sebastián de los Reyes (Madrid) Spania
English: 2 Ellinikou Str 16777,Elliniko, Athens Greece
Romanian: 2 Ellinikou Str 16777,Elliniko, Athens Grecia
English: 13500 HÄMEENLINNA Finland
Romanian: 13500 HÄMEENLINNA Finlanda
English: Mylan Sas 117, allée des Parcs 69800 Saint-Priest France
Romanian: Mylan Sas 117, allée des Parcs 69800 Saint-Priest Franţa
English: Hameenlinna Finland
Romanian: Hameenlinna Finlanda
English: Belgium Mylan BVBA/SPRL Terhulpsesteenweg 6A,
Romanian: Mylan BVBA/SPRL Terhulpsesteenweg 6A,
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the Member States
Romanian: Lista cu denumirile comerciale, formele farmaceutice, concentraţiile, căile de administrare ale medicamentelor, deţinătorii autorizaţiei de punere pe piaţă în Statele Membre
English: Benzstr.1 D-61352
Romanian: KG Benzstr.1 D-61352
English: 851 01 Bratislava Slovak Republic
Romanian: 851 01 Bratislava Republica Slovacă
English: Belgium Teva Pharma Belgium Laarstraat 16
Romanian: Teva Pharma Belgium Laarstraat 16
English: Tipperary, Ireland
Romanian: Tipperary, Irlanda
English: Actavis Group hf.Reykjavikurvegur 7678 - 220 Hafnarfjörður Iceland
Romanian: Actavis Group hf.Reykjavikurvegur 7678 - 220 Hafnarfjörður Islanda
English: Grønland, NO-0133 Oslo,
Romanian: Grønland, NO-0133 Oslo, Norvegia
English: Teva Sante 110, Esplanade du Général de Gaulle 92931 Paris La Défense Cedex France
Romanian: Teva Sante 110, Esplanade du Général de Gaulle 92931 Paris La Défense Cedex Franţa
English: Bayer Portugal, S.A. Rua Quinta do Pinheiro
Romanian: Portugalia Bayer Portugal, S.A. Rua Quinta do Pinheiro
English: Barcelona Spain
Romanian: Barcelona Spania
English: Norway ratiopharm Oy- Teva Group Menmber, Keilaranta 10 E, 02150 Espoo,
Romanian: Norvegia ratiopharm Oy- Teva Group Menmber, Keilaranta 10 E, 02150 Espoo, Finlanda
English: Souffelweyersheim France
Romanian: Souffelweyersheim Franţa
English: Sweden sanofi-aventis AB Box: 14142
Romanian: Suedia sanofi-aventis AB Box: 14142
English: Germany Berlin-Chemie AG Glienicker Weg 125
Romanian: Germania Berlin-Chemie AG Glienicker Weg 125
English: Societe Cilfa Developpement 20, Rue Jean Daudin 75015 - Paris France
Romanian: Societe Cilfa Developpement 20, Rue Jean Daudin 75015 - Paris Franţa
English: 37, rue Saint-Romain 69379 Lyon Cedex 08 France
Romanian: 37, rue Saint-Romain 69379 Lyon Cedex 08 Franţa
English: 2012 HK Haarlem The Netherlands
Romanian: 2012 HK Haarlem Olanda
English: Chefaro Ireland Limited, First Floor, Block A, The Crescent Building, Northwood Office Park, Dublin 9, Ireland
Romanian: Chefaro Ireland Limited, First Floor, Block A, The Crescent Building, Northwood Office Park, Dublin 9, Irlanda
English: Sweden Evolan Pharma AB Box: 120
Romanian: Evolan Pharma AB Box: 120
English: B-1560 Hoeilaart Belgium
Romanian: B-1560 Hoeilaart Belgia
English: Belgium Sterop Laboratoires nv Avenue de Scheut 46
Romanian: Sterop Laboratoires nv Avenue de Scheut 46
English: Denmark Amgros I/S, Dampfærgevej 22, DK-2100 København Ø, Denmark
Romanian: Danemarca Amgros I/S, Dampfærgevej 22, DK2100 København Ø, Danemarca
English: SW1V 2SA United Kingdom
Romanian: SW1V 2SA Marea Britanie
English: 22 quai Gallieni 92150 Suresnes France
Romanian: 22 quai Gallieni 92150 Suresnes Franţa
English: 10237 Dolni Mecholupy Czech Republic
Romanian: 10237 Dolni Mecholupy Republica Cehă
English: 69007 Lyon France
Romanian: 69007 Lyon Franţa
English: Denmark Takeda Pharma A/S, Langebjerg 1, DK4000 Roskilde
Romanian: Danemarca Takeda Pharma A/S, Langebjerg 1, DK4000 Roskilde
English: 69151 Décines Cedex France
Romanian: 69151 Décines Cedex Franţa
English: 08228 Tarrasa (Barcelona) Spain
Romanian: 08228 Tarrasa (Barcelona) Spania
English: Sweden Meda AB Box 906
Romanian: Meda AB Box 906
English: Luxembourg Laboratoires SMB S.A. Rue de la Pastorale 26- 28 B 1080
Romanian: Luxemburg Laboratoires SMB S.A. Rue de la Pastorale 26- 28 B 1080
English: Omega Pharma Baltics SIA, K. Ulmana 119, Marupe, LV-2167, Latvia
Romanian: Omega Pharma Baltics SIA, K. Ulmana 119, Marupe, LV-2167, Letonia
English: 92700 Colombes France
Romanian: 92700 Colombes Franţa
English: 032266 Bucureşti, Romania codeinum
Romanian: 032266 Bucureşti, România codeină
English: Luxembourg MEDA PHARMA 25 boulevard de l'amiral Bruix F-75016 Paris France
Romanian: Luxemburg MEDA PHARMA 25 boulevard de l'amiral Bruix F-75016 Paris Franţa
English: Bayer Limited, The Atrium, Blackthorn Road, Dublin 18, Ireland
Romanian: Bayer Limited, The Atrium, Blackthorn Road, Dublin 18, Irlanda
English: FARMALIDER, S.A. Aragoneses, 15 28108 Madrid Spain
Romanian: FARMALIDER, S.A. Aragoneses, 15 28108 Madrid Spania
English: Sweden Recip AB Box: 906
Romanian: Recip AB Box: 906
English: Denmark Alternova A/S, Lodshusvej 11, DK4230 Skælskør, Denmark
Romanian: Danemarca Alternova A/S, Lodshusvej 11, DK4230 Skælskør, Danemarca
English: S.C. MAGISTRA C & C S.R.L.Bd-ul Aurel Vlaicu nr. 82 A, Constanţa,
Romanian: S.C. MAGISTRA C & C S.R.L.Bd-ul Aurel Vlaicu nr. 82 A, Constanţa, România codeină
English: Aspar Pharmaceuticals Limited, 29-30 Capitol Way, Colindale, London NW9 0EQ United Kingdom
Romanian: Aspar Pharmaceuticals Limited, 29-30 Capitol Way, Colindale, London NW9 0EQ Marea Britanie
English: C/ Anabel Segura, 11 Edificio Albatros B, 1ª planta
Romanian: TEVA PHARMA, S.L.U. C/ Anabel Segura, 11 Edificio Albatros B, 1ª planta
English: Hämeenlinna 13500 Finland paracetamol, codeine,
Romanian: Hämeenlinna 13500 Finlanda paracetamol, codeină,
English: Ziduri între Vii nr.22, Bucureşti, sector 3, 023324
Romanian: S.C. SINTOFARM S.A.Str. Ziduri între Vii nr.22, Bucureşti, sector 3, 023324
English: Luxembourg Meda Pharma GmbH&Co.
Romanian: Luxemburg Meda Pharma GmbH&Co.
English: Belgium Laboratoires SMB SA rue de la Pastorale 26
Romanian: Laboratoires SMB SA rue de la Pastorale 26
English: CIPLA (EU) LIMITED, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW United Kingdom
Romanian: CIPLA (EU) LIMITED, Hillbrow House, Hillbrow Road, Esher, Surrey, KT10 9NW Marea Britanie
English: Germany Dr. R. Pfleger Chemische Fabrik GmbH
Romanian: Germania Dr. R. Pfleger Chemische Fabrik GmbH
English: 00101 Helsinki Finland
Romanian: 00101 Helsinki Finlanda
English: Luxembourg Bristol-Myers Squibb Belgium S.A. Avenue de Finlande, 8 B-1420
Romanian: Luxemburg Bristol-Myers Squibb Belgium S.A. Avenue de Finlande, 8 B-1420
English: 92517 Boulogne Billancourt Cedex France
Romanian: 92517 Boulogne Billancourt Cedex Franţa
English: MAX REMEDIES LIMITED, Stoney Gate House, 2 Greenfield Road, Holmfirth, West Yorkshire, HD9 2JT, United Kingdom
Romanian: MAX REMEDIES LIMITED, Stoney Gate House, 2 Greenfield Road, Holmfirth, West Yorkshire, HD9 2JT, Marea Britanie
English: Nitrianska 100, Hlohovec 920 27 Slovak Republic codeine
Romanian: Nitrianska 100, Hlohovec 920 27 Republica Slovacă codeină
English: 28042 Madrid Spain
Romanian: 28042 Madrid Spania
English: 00351 Helsinki Finland
Romanian: 00351 Helsinki Finlanda
English: Germany Merck Serono GmbH Alsfelder Str. 17
Romanian: Germania Merck Serono GmbH Alsfelder Str. 17
English: Niepodleglosci 18 02-653 Warsaw Poland
Romanian: 02-653 Warsaw Polonia
English: 92300 Levallois-Perret France
Romanian: 92300 Levallois-Perret Franţa
English: 75014 Paris France
Romanian: 75014 Paris Franţa
English: Azur compositum SC Suppositorien suppository rectal use
Romanian: Azur compositum SC Suppositorien supozitor administrare rectală
English: FOURRTS (UK)PHARMACARE LIMITED, 30 Chaul End Lane, Luton, Bedfordshire, LU4 8EZ, United Kingdom
Romanian: FOURRTS (UK)PHARMACARE LIMITED, 30 Chaul End Lane, Luton, Bedfordshire, LU4 8EZ, Marea Britanie
English: Algocod powder
Romanian: Algocod pulbere
English: ibuprofen + codeine Nurofen Plus
Romanian: ibuprofen + codeină Nurofen Plus